These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8315551)

  • 1. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.
    Buts JP; Corthier G; Delmee M
    J Pediatr Gastroenterol Nutr; 1993 May; 16(4):419-25. PubMed ID: 8315551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of Clostridium difficile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study.
    Castex F; Corthier G; Jouvert S; Elmer GW; Lucas F; Bastide M
    J Gen Microbiol; 1990 Jun; 136(6):1085-9. PubMed ID: 2200843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa.
    Castagliuolo I; Riegler MF; Valenick L; LaMont JT; Pothoulakis C
    Infect Immun; 1999 Jan; 67(1):302-7. PubMed ID: 9864230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study.
    Can M; Beşirbellioglu BA; Avci IY; Beker CM; Pahsa A
    Med Sci Monit; 2006 Apr; 12(4):PI19-22. PubMed ID: 16572062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Clostridium difficile in childhood diarrhea.
    Cerquetti M; Luzzi I; Caprioli A; Sebastianelli A; Mastrantonio P
    Pediatr Infect Dis J; 1995 Jul; 14(7):598-603. PubMed ID: 7567289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clostridium difficile toxin A in infants.
    Libby JM; Donta ST; Wilkins TD
    J Infect Dis; 1983 Sep; 148(3):606. PubMed ID: 6619580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis of Clostridium difficile-associated diarrhea and colitis: usefulness of Premier Cytoclone A+B enzyme immunoassay for combined detection of stool toxins and toxigenic C. difficile strains.
    Lozniewski A; Rabaud C; Dotto E; Weber M; Mory F
    J Clin Microbiol; 2001 May; 39(5):1996-8. PubMed ID: 11326033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile and its cytotoxin in diarrhoeic stools of hospitalized patients. Toxigenic potential of the isolates.
    De Barbeyrac B; Guinet R; Quentin C; Cantet P; Bebear C
    Ann Biol Clin (Paris); 1989; 47(2):67-70. PubMed ID: 2660635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Six years evaluation of Clostridium difficile associated diarrhea].
    Ercis S; Ergin A; Hasçelik G
    Mikrobiyol Bul; 2004; 38(1-2):45-50. PubMed ID: 15293901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.
    Akerlund T; Svenungsson B; Lagergren A; Burman LG
    J Clin Microbiol; 2006 Feb; 44(2):353-8. PubMed ID: 16455883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Investigation of toxin genes of Clostridium difficile strains isolated from hospitalized patients with diarrhoea at Marmara University Hospital].
    Deniz U; Ulger N; Aksu B; Karavuş M; Söyletir G
    Mikrobiyol Bul; 2011 Jan; 45(1):1-10. PubMed ID: 21341153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clostridium Difficile, Colitis, and Colonoscopy: Pediatric Perspective.
    McConnie R; Kastl A
    Curr Gastroenterol Rep; 2017 Aug; 19(8):34. PubMed ID: 28707191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii.
    Surawicz CM; McFarland LV; Elmer G; Chinn J
    Am J Gastroenterol; 1989 Oct; 84(10):1285-7. PubMed ID: 2679049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventative agent in gnotobiotic mice.
    Elmer GW; Corthier G
    Can J Microbiol; 1991 Apr; 37(4):315-7. PubMed ID: 1913342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is "negative" positive?
    Surawicz CM
    Am J Gastroenterol; 1999 Oct; 94(10):3060-1. PubMed ID: 10520871
    [No Abstract]   [Full Text] [Related]  

  • 16. Colonization by Clostridium difficile in hospitalized children: risk factors and typification of the isolated strains.
    Camorlinga M; Muñoz O; Guiscafré H; Torres J
    Arch Invest Med (Mex); 1991; 22(1):19-26. PubMed ID: 1819972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal methods for identifying Clostridium difficile infections.
    Gerding DN; Brazier JS
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S439-42. PubMed ID: 8324164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent Clostridium difficile infection in a patient with selective IgG1 deficiency treated with intravenous immune globulin and Saccharomyces boulardii.
    Hassett J; Meyers S; McFarland L; Mulligan ME
    Clin Infect Dis; 1995 Jun; 20 Suppl 2():S266-8. PubMed ID: 7548571
    [No Abstract]   [Full Text] [Related]  

  • 19. [The frequency of Clostridium difficile toxin in neutropenic and non-neutropenic patients with antibiotic-associated diarrhea and analysis of the risk factors].
    Tunçcan OG; Ulutan F; Karakuş R
    Mikrobiyol Bul; 2008 Oct; 42(4):573-83. PubMed ID: 19149078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Clostridium difficile and its cytotoxin in children.
    Merida V; Moerman J; Colaert J; Lemmens P; Vandepitte J
    Eur J Pediatr; 1986 Feb; 144(5):494-6. PubMed ID: 3956538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.